A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

PHASE2,PHASE3

Phase

RECRUITING

Status

1200

Enrollment

OTHER

Sponsor class

Conditions

DRUG: Randomization + Blinatumomab + chemotherapy
OTHER: Randomization + Standard frontline T-ALL chemotherapy backbone
DRUG: Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone
DRUG: Randomization + Blinatumomab + Ponatinib + chemotherapy
OTHER: Randomization 1 + Allo HSCT
OTHER: Randomization 2 + Allo HSCT

Assistance Publique - Hôpitaux de Paris